Market Overview

LakeStreet Analysts Raise NetApp Price Target On Solid Q1 Results


LakeStreet raised its estimates and price target on NetApp Inc. (NASDAQ: NTAP) following the company's first quarter results exceeded consensus in both revenue and EPS.

The results showed that the headwinds in OEM and legacy ONTAP are diminishing with the law of small numbers while AFA and ONTAP 9 transitions are gaining momentum.

Amid "choppy" demand environment, the company's second quarter outlook is in line with consensus. The company expects EPS of $0.51-$0.56 on revenue of $1.27 billion to $1.42 billion, while consensus is at $0.55/$1.33 billion.

Analyst Eric Martinuzzi raised his FY17 EPS estimate to $2.42 from $2.36 while maintaining revenue view at $5.435 billion. The analyst, who maintained his Hold rating on shares, also upped the price target to $31 from $26.

"While we like the company's clustered storage technology and virtualization-friendly architecture, we still face the reality of likely negative comps in product sales in the near term. We believe revenue outperformance in the near term is possible, but it will take a clear path to sustained product growth for us to get more constructive on the shares," Martinuzzi noted.

At time of writing, shares of NetApp surged 16 percent to $33.44.

Latest Ratings for NTAP

Nov 2019MaintainsNeutral
Nov 2019MaintainsOutperform
Nov 2019MaintainsUnderweight

View More Analyst Ratings for NTAP
View the Latest Analyst Ratings

Posted-In: Eric Martinuzzi LakeStreetAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (NTAP)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Quintiles Poised To Benefit From Pharmaceutical R&D Outsourcing

Technical Alert: Valeant Pharmaceuticals Rally Interrupted By Fraud Allegations